Strategic Integration Consort Medical combines Bespak’s drug delivery device heritage with Aesica’s CDMO capabilities, presenting a single-source solution for both drug formulation and delivery devices, which can be positioned as a streamlined, end-to-end partnership for potential customers seeking integrated manufacturing and device development.

Global Expansion Past investments to expand in Germany and Western Europe indicate capacity growth and regional access. Sales outreach can target pharmaceutical companies seeking European manufacturing footprints, faster time-to-market, and localized regulatory readiness.

Nasal Delivery Focus Active development of nasal-delivery solutions for opioid overdoses and overdose reversal devices signals a niche in critical care and addiction treatment. Opportunities exist with specialty pharma and public health programs requiring ready-to-use nasal delivery platforms.

End-to-End CDMO Being a global, single-source CDMO for both API/finished dose and delivery devices allows pitching to mid-market sponsors who want simplified vendor management and synchronized supply chains, reducing project timelines and risk.

Leadership & Investment Recent governance appointments and ongoing innovation investments can be leveraged to reassure prospects about long-term stability, technical leadership, and a commitment to patient- and customer-driven innovation when engaging in high-stakes collaborations.